帕奎莫德
| 中文名称 | 帕奎莫德 |
|---|---|
| 中文同义词 | 帕奎莫德;N,5-二乙基-4-羟基-1-甲基-2-氧代-N-苯基-1,2-二氢喹啉-3-甲酰胺;化合物PAQUINIMOD |
| 英文名称 | Paquinimod |
| 英文同义词 | Paquinimod;ABR?215757;N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide;ABR 25757;ABR 25757;ABR-25757;ABR25757;PAQUINIMOD;248282-01-1;ABR25757;ABR-25757;ABR?215757; ABR 215757; ABR215757; PAQUINIMOD. |
| CAS号 | 248282-01-1 |
| 分子式 | C21H22N2O3 |
| 分子量 | 350.41 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 248282-01-1.mol |
| 结构式 |  |
帕奎莫德 性质
| 沸点 | 487.3±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.267±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO:15.0(最大浓度 mg/mL);42.8(最大浓度 mM) |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.50±1.00(Predicted) |
S100A9
S100A9 is a calcium-binding protein of the S100 family. Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. Prophylactic treatment with S100A9 inhibitor Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Paquinimod is a potent inhibitor of insulitis and diabetes development in the NOD mouse. To assess the preventive efficacy of Paquinimod on diabetes development in female NOD mice, groups of mice are treated with daily doses of 0.04, 0.2, 1, and 5 mg/kg/day of Paquinimod from week 10 of age until week 20 of age. Glycosuria is analyzed on a weekly basis from 10 weeks of age until the endpoint of the experiment at 40 weeks of age. There is a clear dose-dependent reduction in diabetes development in the Paquinimod-treated mice.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-100442 | Paquinimod | 5 mg | 930元 | |
| 2024/04/30 | HY-100442 | 帕奎莫德 Paquinimod | 248282-01-1 | 10mM * 1mLin DMSO | 1020元 |